Infectious Diseases

The study outcomes were estimated IMD cases and deaths averted by MenACWY vaccination in adolescents and adults aged 11 to 23 years.

Severe outcomes among children with pneumonia were uncommon, regardless of whether antibiotics were received based on study results.

"The novel RSV prevention strategies may reduce ICU morbidity and mortality for children," the study authors concluded.

Look back at several quick video interviews discussing the expanding role of artificial intelligence, how RSV treatment has evolved, and much more.

Donna Hallas, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights key takeaways from our October Vaccine issue of Contemporary Pediatrics.

HPV vaccination in Brazil led to significant reductions in genital warts and cervical precancer hospitalizations, especially among those under 20 years of age.

Panama’s switch to the 9-valent HPV vaccine promises greater protection and reduced cancer rates, preventing thousands of HPV-related cases and deaths.

There were no treatment or RSV-related deaths during the study.

Overall, 2 doses of TAK-003 successfully induced the production of neutralizing antibodies against all 4 dengue serotypes in at least 90% of adults, children, and adolescents, regardless of whether they were seronegative or seropositive at baseline.

Trivalent seasonal influenza vaccines include 2 influenza A viruses (H1N1) and 1 influenza B virus.

A single dose of the mRNA-1273.222 vaccine demonstrated strong immune responses against various omicron subvariants and showed a favorable safety profile compared to existing vaccines.

With this approval, FluMist becomes the first vaccine to prevent influenza that does not need to be administered by a health care provider.

The CDC committee has set new recommendations based on children's age, vaccination status, and overall immunity health, for the 2024 - 2025 period.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the August 2024 issue of Contemporary Pediatrics.

In this episode, clinicians discuss challenges associated with these topics and offer some insights on them.

IIV3s, RIV3, and LAIV3 influenza vaccines are expected to be available.

The federal agency advised manufacturers in June that 2024-2025 COVID-19 vaccines should be monovalent JN.1, with the preferred lineage being the KP.2 strain.

Healthcare providers should maintain heightened suspicion of parvovirus B19 in individuals presenting with symptoms, particularly those at high risk.

Among children born in 2020, vaccination coverage was 4 to 14 percentage points lower among those who were eligible for VFC versus non-eligible children.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the August 2024 issue of Contemporary Pediatrics.

Merck announced clesrovimab met all primary safety and efficacy endpoints, with additional detailed findings to be presented at an upcoming scientific congress.

As of July 19, 2024, there were 28 Listeria illnesses and 2 deaths linked to meats sliced at delis.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Despite extensive efforts, there remains no approved vaccine for norovirus, HilleVax decided to focus on a different development, a Phase 1 ready vaccine candidate for adults.

Donna Hallas. PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, underscores the critical need for proper vaccination and effective communication between parents and schools to ensure sick children stay home, while addressing logistical challenges faced by parents.

Matthew M Davis, MD, MAPP, elaborates on how higher COVID-19 vaccination rates may curb the virus, alleviate childhood asthma symptoms, and protect against other common colds.

Results confirmed that a bedaquiline-containing regimen offered a significant improvement in treatment outcomes compared to injectable-containing regimens.

Experts highlight common waterborne illnesses, preventive tips for summer.

Unexpected seasonal RSV following COVID-19 highlighted the need for ongoing research to better understand transmission and ongoing impact from the pandemic.

Over the winter, the omicron JN.1 lineages overtook XBB strains as dominant.